Amgen Mum On Repatha Sales; Outcomes Data Needed To Sway US Payers
This article was originally published in Scrip
Amgen Inc.'s 2015 revenue of $21.66bn, up 8% from the prior year, met analyst consensus expectations, but one of the biggest questions of all was left unanswered: How many millions of dollars in sales of the PCSK9 inhibitor Repatha (evolocumab) has the company generated so far?
You may also be interested in...
The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.